Increased CCL19 expression is associated with progression in cervical cancer

Zhang, Xiaoshu; Wang, Yue; Cao, Yanning; Zhang, Xueshan; Zhao, Haiya

doi:10.18632/oncotarget.17982

Cited by 36 publications

(24 citation statements)

References 25 publications

(24 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…T cells expressing CCR7, in contrast with CD56 bright NK cells, did not increase in the blood of stage IV melanoma patients, suggesting that T cells may overcome the increased CCL19 sera concentration and redistribute to peripheral tissues. The scenario emerging from our study is that melanoma cells and related CSCs may produce CCL19, as described for cervical cancer (41). The increased serum concentration of CCL19 found in stage IV melanoma patients could be explained by the higher disease burden, where an increased number of CSCs actively secrete the chemokine.…”

Section: Discussionmentioning

confidence: 56%

Accumulation of Circulating CCR7+ Natural Killer Cells Marks Melanoma Evolution and Reveals a CCL19-Dependent Metastatic Pathway

Cristiani

Turdo

Ventura

et al. 2019

Cancer Immunology Research

View full text Add to dashboard Cite

Immune checkpoint blockade therapy has changed prognoses for many melanoma patients. However, immune responses that correlate with clinical progression of the disease are still poorly understood. To identify immune responses correlating with melanoma clinical evolution, we analyzed serum cytokines as well as circulating NK and T cell subpopulations from melanoma patients. The patients' immune profiles suggested that melanoma progression leads to changes in peripheral blood NK and T cell subsets. Stage IV melanoma was characterized by an increased frequency of CCR7 + CD56 bright NK cells as well as high serum concentrations of the CCR7-ligand CCL19. CCR7 expression and CCL19 secretion were also observed in melanoma cell lines. The CCR7 + melanoma cell subpopulation co-expressed PD-L1 and Galectin-9 and had stemness properties. Analysis of melanoma-derived cancer stem cells (CSCs) showed high CCR7 expression; these CSCs were efficiently recognized and killed by NK cells. An accumulation of CCR7 + , PD-L1 + and Galectin-9 + melanoma cells in melanoma metastases was demonstrated ex vivo. Altogether, our data identify biomarkers that may mark a CCR7-driven metastatic melanoma pathway.

show abstract

Section: Discussionmentioning

confidence: 56%

Accumulation of Circulating CCR7+ Natural Killer Cells Marks Melanoma Evolution and Reveals a CCL19-Dependent Metastatic Pathway

Cristiani

Turdo

Ventura

et al. 2019

Cancer Immunology Research

View full text Add to dashboard Cite

show abstract

“…et al, 2017 ), and it also exhibits transcriptional repression by epigenetic inactivation in specific cervical cancer cell lines, thus it may contribute to the constitutive activation of the Wnt signaling pathway in cervical carcinogenesis ( Lee et al, 2008 ). A large number of studies have demonstrated that chemokines are involved in the progression, migration, and survival of cancers, such as CXCL12 (ENSG00000107562), CCL21 (ENSG00000137077), and especially CCL19 (ENSG00000172724), which is associated with progression of cervical cancer ( Teicher and Fricker, 2010 ; Xiong et al, 2017 ; Zhang et al, 2017 ). Homeobox B13 (HOXB13, ENSG00000159184) is a susceptibility gene for prostate cancer ( Xu et al, 2013 ).…”

Section: Discussionmentioning

confidence: 99%

Identification of Novel Long Non-coding and Circular RNAs in Human Papillomavirus-Mediated Cervical Cancer

et al. 2017

View full text Add to dashboard Cite

Cervical cancer is the third most common cancer worldwide and the fourth leading cause of cancer-associated mortality in women. Accumulating evidence indicates that long non-coding RNAs (lncRNAs) and circular RNAs (circRNAs) may play key roles in the carcinogenesis of different cancers; however, little is known about the mechanisms of lncRNAs and circRNAs in the progression and metastasis of cervical cancer. In this study, we explored the expression profiles of lncRNAs, circRNAs, miRNAs, and mRNAs in HPV16 (human papillomavirus genotype 16) mediated cervical squamous cell carcinoma and matched adjacent non-tumor (ATN) tissues from three patients with high-throughput RNA sequencing (RNA-seq). In total, we identified 19 lncRNAs, 99 circRNAs, 28 miRNAs, and 304 mRNAs that were commonly differentially expressed (DE) in different patients. Among the non-coding RNAs, 3 lncRNAs and 44 circRNAs are novel to our knowledge. Functional enrichment analysis showed that DE lncRNAs, miRNAs, and mRNAs were enriched in pathways crucial to cancer as well as other gene ontology (GO) terms. Furthermore, the co-expression network and function prediction suggested that all 19 DE lncRNAs could play different roles in the carcinogenesis and development of cervical cancer. The competing endogenous RNA (ceRNA) network based on DE coding and non-coding RNAs showed that each miRNA targeted a number of lncRNAs and circRNAs. The link between part of the miRNAs in the network and cervical cancer has been validated in previous studies, and these miRNAs targeted the majority of the novel non-coding RNAs, thus suggesting that these novel non-coding RNAs may be involved in cervical cancer. Taken together, our study shows that DE non-coding RNAs could be further developed as diagnostic and therapeutic biomarkers of cervical cancer. The complex ceRNA network also lays the foundation for future research of the roles of coding and non-coding RNAs in cervical cancer.

show abstract

“…Chemokine CC ligand 19 (CCL19), which is also named as macrophage inflammatory protein 3-beta (MIP-3b), mediates various cellular behaviors by binding to CCR7 10 . Recent articles have indicated that the CCL19/CCR7 axis can promote tumor progression 11 , 12 . Nevertheless, some other studies indicated that CCL19 can modulate anti-tumor responses in lung cancer and ovarian cancer 13 , 14 .…”

Section: Introductionmentioning

confidence: 99%

CCL19 suppresses angiogenesis through promoting miR-206 and inhibiting Met/ERK/Elk-1/HIF-1α/VEGF-A pathway in colorectal cancer

et al. 2018

View full text Add to dashboard Cite

The mechanisms underlying the role of chemokines in tumor angiogenesis is still not fully understood. In this study, we detected the influence of CCL19 on colorectal cancer (CRC) angiogenesis. The expression of CCL19 and CD31 in CRC tissues were detected by immunohistochemistry. Human CRC cell lines SW1116 and SW620 stably transfected with CCL19 lentivirus and CCL19 shRNA, and HUVEC stably transfected with CCR7 shRNA were used in our study. Our study showed that CCL19 was significantly low-expressed in CRC tissues and positively related to highly tumor microvessel density. In vitro, we observed that CCL19 high-expressed SW1116 supernatant was able to inhibit proliferation, migration, and sprouting responses of HUVEC, whereas CCL19 low-expressed SW620 supernatant can promote HUVEC angiogenesis. Additionally, we further demonstrated that these functions maybe achieved through promoting miR-206 thus inhibiting Met/ERK/Elk-1/HIF-1α/VEGF-A pathway in a CCR7-dependent manner. Mice angiogenesis model also confirmed that elevated expression of CCL19 inhibit the angiogenesis of CRC in vivo. In summary, our results supported that CCL19 can inhibit CRC angiogenesis through promoting miR-206 thus inhibiting Met/ERK/Elk-1/HIF-1α/VEGF-A pathway. This may be a novel therapeutic option for anti-vascular treatment in CRC.

show abstract

Increased CCL19 expression is associated with progression in cervical cancer

Cited by 36 publications

References 25 publications

Accumulation of Circulating CCR7+ Natural Killer Cells Marks Melanoma Evolution and Reveals a CCL19-Dependent Metastatic Pathway

Accumulation of Circulating CCR7+ Natural Killer Cells Marks Melanoma Evolution and Reveals a CCL19-Dependent Metastatic Pathway

Identification of Novel Long Non-coding and Circular RNAs in Human Papillomavirus-Mediated Cervical Cancer

CCL19 suppresses angiogenesis through promoting miR-206 and inhibiting Met/ERK/Elk-1/HIF-1α/VEGF-A pathway in colorectal cancer

Contact Info

Product

Resources

About